Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Acorda Therapeutics Inc.
DescriptionInhaled formulation of zolmitriptan, a serotonin (5-HT1B) and 5-HT1D receptor agonist, using Arcus inhalation technology
Molecular Target Serotonin (5-HT1B) receptor ; Serotonin (5-HT1D) receptor
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationMigraine
Indication DetailsTreat acute migraine
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today